ReviewAdvanced biotechnology2026
Duckweeds: from fundamental biology to a sustainable plant chassis for biotechnology.
Review in Advanced biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Duckweeds (Lemnaceae), the smallest and fastest-growing flowering plants, have emerged as a transformative platform for sustainable biotechnology. This review synthesizes recent advances that underpin their potential as a next-generation plant chassis. We discuss duckweed's unique biology, characterized by reductive evolution, extreme phenotypic plasticity, and a simplified epigenome that favors transgene expression. The decoding of its minimalist genome, along with the establishment of efficient genetic tools including optimized transformation and CRISPR-Cas9 editing, enables precise genetic and metabolic engineering. While traditional uses in phytoremediation and animal feed validate its utility, duckweed's rapid growth in contained, soil-free culture and its edibility offer distinct advantages for molecular farming over established systems like tobacco. We highlight progress in engineering duckweeds to produce vaccines, therapeutic proteins, and high-value metabolites. To transition from proof-of-concept to an industrial workhorse, future efforts must focus on integrated omics databases, universal genetic toolkits, and scalable cultivation. Converging fundamental insights with synthetic biology principles positions duckweed as a versatile and powerful chassis for the bioeconomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.